BioSpace News Archive

Calidi Biotherapeutics Inc. and City of Hope jointly announced that the CIRM has awarded Karen Aboody, M.D., City of Hope professor in the Department of Stem Cell Biology and Regenerative Medicine and Division of Neurosurgery, a $5.3 million grant to fund preclinical translational studies, product manufacturing, and clinical trial design using Calidi’s licensed oncolytic virotherapy product, CLD-101, in patients with chemo-resistant, metastatic ovarian cancer.

Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended December 31, 2023 and provided an update on key corporate milestones.

Redwire Corporation announced today that Redwire Chief Financial Officer Jonathan Baliff will present at the 36th Annual ROTH Conference on March 18, 2024 from 8:30-8:55 a.m. PT.

Biora Therapeutics, Inc. today announced an agreement with institutional investor Context Capital to invest $2.8 million in new capital.

Allyx Therapeutics announced that its lead compound, ALX-001, is ready to proceed to Phase 2 clinical development in Alzheimer’s and Parkinson’s disease.

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced long-term data from a Phase 2b clinical trial of izokibep in hidradenitis suppurativa (HS).

ACELYRIN, INC. today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance.

Daxor Corporation, the global leader in blood volume measurement technology announces the expansion of blood volume analysis in three new hospitals through new analyzer purchases, and the utilization of Daxor’s ezBVA Lab service.

TiumBio Co., Ltd. announced that it has submitted Investigational New Drug (IND) application to the Korean Ministry of Food and Drug Safe (MFDS) for a Phase 2a study of TU2218, an oral immuno-oncology drug, in late February, 2024 and that preclinical results of TU2218 will be presented at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting.

Synnovation Therapeutics today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.